Difficulty: Medium
Average Score: 94%
Practice
Which one of the following hypnotic benzodiazepines is more likely to cause rebound insomnia?
Correct answer
A
Rationale
In this question, the correct answer is A) Triazolam. Triazolam is a short-acting benzodiazepine with a rapid onset of action and short half-life, making it more likely to cause rebound insomnia. Rebound insomnia occurs when the body becomes dependent on the medication to fall asleep, and when the medication is discontinued, the insomnia worsens temporarily.
Flurazepam and Temazepam are longer-acting benzodiazepines with less likelihood of causing rebound insomnia compared to Triazolam. Flurazepam has a long half-life and is typically used for maintaining sleep rather than initiating sleep. Temazepam is an intermediate-acting benzodiazepine commonly used for insomnia, but its risk of rebound insomnia is lower than that of Triazolam.
Selecting "All of the above" (option D) is incorrect because not all hypnotic benzodiazepines are equally likely to cause rebound insomnia. Understanding the differences in onset of action, half-life, and overall pharmacokinetics of these medications is crucial in determining their potential for rebound insomnia.
In an educational context, this question highlights the importance of selecting the appropriate hypnotic benzodiazepine based on individual patient factors and desired treatment outcomes. Healthcare providers need to consider factors such as duration of action, risk of dependency, and rebound effects when prescribing these medications for insomnia management. Understanding these nuances can help optimize treatment efficacy while minimizing potential adverse effects.
Flurazepam and Temazepam are longer-acting benzodiazepines with less likelihood of causing rebound insomnia compared to Triazolam. Flurazepam has a long half-life and is typically used for maintaining sleep rather than initiating sleep. Temazepam is an intermediate-acting benzodiazepine commonly used for insomnia, but its risk of rebound insomnia is lower than that of Triazolam.
Selecting "All of the above" (option D) is incorrect because not all hypnotic benzodiazepines are equally likely to cause rebound insomnia. Understanding the differences in onset of action, half-life, and overall pharmacokinetics of these medications is crucial in determining their potential for rebound insomnia.
In an educational context, this question highlights the importance of selecting the appropriate hypnotic benzodiazepine based on individual patient factors and desired treatment outcomes. Healthcare providers need to consider factors such as duration of action, risk of dependency, and rebound effects when prescribing these medications for insomnia management. Understanding these nuances can help optimize treatment efficacy while minimizing potential adverse effects.